VCEL — Vericel Corporation stock price, charts and financials

Latest market price

46.34

+0.29+0.63%

Overview Short InterestFilings

VCELQT59Vericel Corporation·NASDAQ

Overview Short InterestFilings

46.34+0.63%

Loading chart...

Signal & projected range

Earnings big beat — drift (PEAD)Historical pattern — not a prediction

Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)

Horizon

Unlock the projected rangeSee where this setup landed historically — with Premium.

Unlock with Premium

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Unlock with Premium to see the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands of historical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →

PHVS+5.02%$33.87 ANAB+2.74%$55.13 KLRA+4.56%$18.11 IMNM+8.91%$25.06 MLYS+2.79%$26.50 PGEN-1.21%$6.53 AMLX+8.43%$21.87 BCRX+2.38%$9.02

Snapshot

Index	-	P/E	98.60	EPS (ttm)	0.47	Insider Own	1.83%	Shs Outstand	51.07M	Perf Week	-0.79%

Market Cap	2.37B	Forward P/E	52.66	EPS next Y	0.88	Insider Trans	-15.16%	Shs Float	50.44M	Perf Month	-0.47%

Enterprise Value	2.30B	PEG	2.37	EPS next Q	0.08	Inst Own	-	Short Float	9.13%	Perf Quarter	26.99%

Income	24.00M	P/S	7.73	EPS this Y	16.76%	Inst Trans	-	Short Ratio	7.18	Perf Half Y	25.45%

Sales	306.00M	P/B	6.40	EPS next Y	60.36%	ROA	4.82%	Short Interest	4.60M	Perf YTD	28.69%

Book/sh	7.25	P/C	14.61	EPS next 5Y	41.66%	ROE	6.91%	52W High	49.32 -6.04%	Perf Year	30.06%

Cash/sh	3.17	P/FCF	47.28	EPS past 3/5Y	- 39.49%	ROIC	3.79%	52W Low	28.95 60.07%	Perf 3Y	22.66%

Dividend Est.	-	EV/EBITDA	58.88	Sales past 3/5Y	18.95% 17.35%	Gross Margin	74.56%	Volatility	3.88% 3.52%	Perf 5Y	-13.07%

Dividend TTM	-	EV/Sales	7.50	EPS Y/Y TTM	135.00%	Oper. Margin	5.95%	ATR (14)	1.73	Perf 10Y	2075.59%

Dividend Ex-Date	-	Quick Ratio	4.69	Sales Y/Y TTM	29.11%	Profit Margin	7.91%	RSI (14)	56.29	Recom	2.36

Dividend Gr. 3/5Y	-	Current Ratio	5.04	EPS Q/Q	-	SMA20	-0.17%	Beta	1.05	Target Price	57.50

Payout	0.00%	Debt/Eq	0.28	Sales Q/Q	22.22%	SMA50	10.18%	Rel Volume	0.69	Prev Close	46.05

Employees	398	LT Debt/Eq	0.24	Earnings	Nov 05	SMA200	23.54%	Avg Volume	634.89K	Price	46.34

IPO Date	Feb 04, 1997	Option/Short	Yes / Yes	EPS/Sales Surpr.	238.23% 6.54%	Net Debt/EBITDA	-0.85	Volume	439,563	Change	0.63%

Analyst Ratings

Date	Action	Analyst	Rating	Target
Jul-30-26	Reiterated	Canaccord Genuity	Buy	$60
Jul-16-26	Reiterated	Truist Securities	Buy	$42 → $54
May-08-26	Reiterated	HC Wainwright & Co.	Buy	$60 → $70
Apr-15-26	Reiterated	Truist Securities	Buy	$45 → $42
Mar-10-26	Reiterated	Leerink Partners		$46
Dec-18-25	Reiterated	Truist Securities	Buy	$41 → $45
Oct-15-25	Reiterated	Truist Securities	Buy	$67 → $41
Sep-17-25	Downgrade	BTIG	Buy → Neutral
Dec-18-24	Reiterated	Truist Securities	Buy	$57 → $67
Aug-26-24	Reiterated	BTIG	Buy	$56 → $55

Latest News

Jul-31-26

Jul-31-2601:46PM

TD Cowen Maintains Buy on Vericel, Raises Price Target to $58Benzinga

Jul-30-26

Jul-30-2605:04PM

Vericel Q2 Earnings Call Highlightsmarketbeat.com

12:54PM

Vericel Corporation (VCEL) Q2 2026 Earnings Call Transcriptseekingalpha.com

10:36AM

Vericel Corporation (VCEL) Beats Q2 Earnings and Revenue Estimateszacks.com

07:55AM

Vericel Reports Second Quarter 2026 Financial Results, Raises Full-Year Financial Guidance and Announces Share Repurchase Programglobenewswire.com

Jul-28-26

Jul-28-2606:03AM

HC Wainwright & Co. Reiterates Buy on Vericel, Maintains $70 Price TargetBenzinga

Jul-21-26

Jul-21-2610:30AM

Vericel Corp (NASDAQ:VCEL): Strong Growth Stock With a Bull Flag Breakout SetupChartMill

03:08AM

Vericel Corporation $VCEL Shares Sold by Allspring Global Investments Holdings LLCdefenseworld.net

Jul-18-26

Jul-18-2611:20AM

Vericel Corp (NASDAQ:VCEL): An Affordable Growth Stock at a Reasonable ValuationChartMill

Jul-16-26

Jul-16-2608:30AM

Vericel to Report Second Quarter 2026 Financial Results on July 30, 2026globenewswire.com

Jun-27-26

Jun-27-2605:18PM

Vericel Stock Is Up 10%. Here's What This $402,000 Insider Sale Really SuggestsYahoo

Jun-26-26

Jun-26-2611:50AM

Vericel Corp (NASDAQ:VCEL): A Classic Affordable Growth Stock in BiotechChartMill

Jun-16-26

Jun-16-2608:10AM

Vericel Corp (NASDAQ:VCEL): Growth and Technical Setup Align for Potential BreakoutChartMill

Company

Vericel Corporation operates as a biopharmaceutical firm that has reached the commercialization phase, specializing in the research, development, production, and distribution of cell-based treatments. Its primary therapeutic areas are sports medicine and critical burn care across the United States. The company's product lineup includes MACI, an autologous cellularized scaffold employed for mending symptomatic, full-thickness cartilage damage in the knee, and Epicel, a permanent skin replacement designated as a humanitarian use device for treating deep-dermal or full-thickness burns in both adults and children. Additionally, Vericel is progressing NexoBrid, an orphan biological product currently in the registration phase, which aims to remove eschar from deep partial-thickness or full-thickness thermal burns in adults. Established in 1989 under its former name, Aastrom Biosciences, Inc., the company is headquartered in Cambridge, Massachusetts.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements

DataTimeframe

Line Item (USD, M)	TTM —	FY 2025 12/31/2025	FY 2024 12/31/2024	FY 2023 12/31/2023	FY 2022 12/31/2022	FY 2021 12/31/2021	FY 2020 12/31/2020	FY 2019 12/31/2019	FY 2018 12/31/2018
Total Revenue	306	276	237	198	164	156	124	118	91
Cost of Goods Sold Incl. D&A	78	71	65	62	55	50	40	38	32
Gross Profit	228	206	172	136	110	106	84	80	59
Selling, General and Administrative Excl. Other	180	167	143	121	107	98	69	61	49
Research and Development	28	28	25	21	20	16	13	30	14
Other Operating Expense	2	0	0	0	0	0	0	1	0
Operating Income	17	11	5	-6	-17	-8	2	-11	-4
Interest Expense	0	2	1	1	0	0	0	0	2
Unusual Expense	—	—	—	—	—	—	—	—	—
Non-Operating Income (Expense)	8	8	7	5	1	0	1	2	-2
Net Income Before Taxes	25	17	11	-2	-16	-8	3	-10	-8
Income Taxes	1	1	0	1	1	0	0	0	0
Consolidated Net Income	24	17	10	-3	-17	-7	3	-10	-8
Net Income From Continuing Operations	24	17	10	-3	-17	-7	3	-10	-8
Net Income	24	17	10	-3	-17	-7	3	-10	-8
EPS (Recurring)	0.48	0.33	0.21	-0.07	-0.35	-0.16	0.06	-0.18	-0.20
EPS (Basic, Before Extraordinaries)	0.48	0.33	0.21	-0.07	-0.35	-0.16	0.06	-0.18	-0.20
EPS (Diluted)	0.47	0.32	0.20	-0.07	-0.35	-0.16	0.06	-0.18	-0.20
EBITDA	39	30	17	3	-12	-5	5	-8	-5
Other After Tax Adjustments	—	—	—	—	—	—	—	—	—
Stock Option Compensation Expense	—	—	—	—	—	—	—	—	—
Price To Earnings Ratio	98.60	112.53	274.55	—	—	—	509.57	—	—
Price To Sales Ratio	7.72	6.65	11.35	8.63	7.55	11.59	11.21	6.49	7.65
Gross Margin	74.51	74.64	72.57	68.69	67.07	67.95	67.74	67.80	64.84
Operating Margin	5.56	3.99	2.11	-3.03	-10.37	-5.13	1.61	-9.32	-4.40
Net Margin	7.84	6.16	4.22	-1.52	-10.37	-4.49	2.42	-8.47	-8.79
Shares Outstanding	51	51	49	48	47	46	45	44	40
Market Capitalization	2,363	1,837	2,691	1,709	1,238	1,808	1,390	766	696
Operating Lease Expense	—	—	—	—	—	—	—	—	—

Unlock full historical data

See years of past statements with Premium.

Unlock with Premium

Insider Trading Volume

Insider Trading

Insider	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
SIEGAL JONATHAN	Principal Accounting Officer	Jul 30 '26	Sale	48.90	500	24,450	1,078	Jul 31
SIEGAL JONATHAN	Principal Accounting Officer	Jul 30 '26	Option Exercise	31.51	9,000	283,620	4,000	Jul 31
Flynn Sean C.	Chief Legal Officer	Jun 26 '26	Option Exercise	16.25	30,000	487,500	55,000	Jun 30
Flynn Sean C.	Chief Legal Officer	Jun 26 '26	Sale	45.64	15,000	684,600	1,647	Jun 30
Hopper Jonathan Mark	Chief Medical Officer	Jun 26 '26	Option Exercise	29.82	15,000	447,300	80,753	Jun 30
Hopper Jonathan Mark	Chief Medical Officer	Jun 26 '26	Sale	45.00	5,000	225,000	75,753	Jun 30
Mara Joseph Anthony Jr	Chief Financial Officer	Jun 26 '26	Sale	44.75	5,000	223,750	16,009	Jun 30
SIEGAL JONATHAN	Principal Accounting Officer	Jun 26 '26	Option Exercise	29.82	5,000	149,100	6,500	Jun 30
SIEGAL JONATHAN	Principal Accounting Officer	Jun 26 '26	Sale	44.90	2,500	112,250	886	Jun 30
Flynn Sean C.	Chief Legal Officer	Jun 18 '26	Option Exercise	16.25	30,000	487,500	70,000	Jun 22
Halpin Michael	Chief Operating Officer	Jun 18 '26	Sale	40.24	10,000	402,400	16,248	Jun 22
Flynn Sean C.	Chief Legal Officer	Jun 18 '26	Sale	40.21	15,000	603,150	1,647	Jun 22
Halpin Michael	Chief Operating Officer	Jun 18 '26	Option Exercise	16.66	20,000	333,200	36,250	Jun 22
Hopper Jonathan Mark	Chief Medical Officer	Jun 02 '26	Option Exercise	16.66	8,750	145,776	80,128	Jun 04
Hopper Jonathan Mark	Chief Medical Officer	Jun 02 '26	Sale	35.00	4,375	153,125	75,753	Jun 04

open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR

QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.